Olema Pharmaceuticals, Inc. (OLMA): Total Assets
$533.43M
As of 2025-12-31
$486.58M
As of 2026-06-30
+35.2%
3-year compound annual growth
+9.3%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $533.43M | +18.3% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $450.98M | +62.8% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $276.94M | +28.4% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $215.65M | -27.1% | 2024-03-11, Balance as of period end |
| 2021-12-31 | $295.94M | -13.6% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $342.72M | n/a | 2022-02-28, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | 2025-12-31 | $533.43M | +18.3% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $530.92M | +42.0% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $529.71M | -26.9% |
| Edgewise Therapeutics, Inc. (EWTX) | 2025-12-31 | $552.60M | +13.5% |
| Rigel Pharmaceuticals Inc (RIGL) | 2025-12-31 | $513.59M | +213.2% |
| Rapport Therapeutics, Inc. (RAPP) | 2025-12-31 | $512.43M | +62.7% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $501.60M | +15.1% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $567.75M | -7.3% |
| Geron Corp (GERN) | 2025-12-31 | $570.54M | -3.9% |
Compare OLMA, DNTH, SNDX, EWTX side by side · Screen every company in Pharmaceutical Preparations ↗